1. US senator introduces a ‘Right to Try’ bill for desperate. By Ed Silverman (Pharmalot). [cited 2016 May 10]. Available from: patientswww.https://www.statnews.com/pharmalot/2016/05/10/fda-experimental-drugs-right-to-try/.
2. Expanded Access to Investigational Drugs. What physicians and the public need to know about FDA and corporate processes. Paige E. Finkelstein. [cited 2015 Dec]. Available from: www.http://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm20041768.htm.
3. The hidden cost of crowd-sourcing a cure. Helen Ouyang. [cited 2016 Jun]. Available from: www.http://harpers.org/archive/2016/06/hashtag-prescription/http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0568-8.
4. Global access programs: a collaborative approach for effective implementation and management. Debra Ainge, Suzanne Aitken, Mark Corbett, David De-Keyzer in Pharmaceutical Medicine. 2015;29(2):79–85. [cited 2016 July 22]. Available from: http://link.springer.com/article/10.1007/s40290-015-0091-9.
5. Lungpacer Medical, Inc. Receives expedited access pathway designation from FDA for the Lungpacer diaphragm pacing system. [cited 2016 May 11]. Available from: http://www.prnewswire.com/news-releases/lungpacer-medical-inc-receives-expedited-access-pathway-designation-from-fda-for-the-lungpacer-diaphragm-pacing-system-300266364.html.